Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

mber 2008. Our ANA773 development costs during the three months ended March 31, 2009 were primarily driven by our on-going Phase I clinical trial for the treatment of HCV.

General and administrative expenses remained relatively consistent at approximately $2.1 million for the first quarter of 2009 and $2.0 million for the first quarter of 2008.

Operating expenses were $8.9 million for the first quarter of 2009, compared to $8.1 million for the first quarter of 2008. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $0.7 million for the first quarter of 2009 and 2008.

The net loss was $8.8 million for the first quarter of 2009, compared to a net loss of $7.4 million for the first quarter of 2008. Basic and diluted net loss per common share was $0.30 in the first quarter of 2009 compared to $0.26 in the first quarter of 2008. Non-cash share-based expense resulted in a $0.02 increase in basic and diluted net loss per share for the three months ended March 31, 2009 and 2008.

Development Program Highlights

ANA598

ANA598 is an investigational oral non-nucleoside polymerase inhibitor that Anadys is developing for the treatment of chronic hepatitis C virus (HCV) infection. Three Phase I trials, including one in HCV patients, are now completed and the program remains on track to be ready in mid-2009 for Phase II studies of ANA598 in combination with current standard of care. The actual timing for the initiation of Phase II studies may depend on a number of factors, including FDA review timelines, the timing of any potential transaction around ANA598 or ANA773, available cash resources and funding activities, and the engagement of clinical sites.

  • Potent Antiviral Activity in HCV. Earlier today, Anadys presented antiviral and safety data from all three dose levels i
    '/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... July 27, 2011 /PRNewswire/ -- bioTheranostics, a ... support targeted disease management, announced today study results published ... Molecular Diagnostics related to the clinical validity and ... classification test to aid in the determination of the ...
... Midwest health care startups reported $315 million in total ... 2011, according to the BioEnterprise Midwest ... ) "While the number of companies funded ... dollars invested is down compared to recent years," said ...
... CHICAGO, July 26, 2011 Linden LLC, a ... it has made an investment in Strata Pathology ... in New England. Headquartered in Lexington, ... dermatology, urology, podiatry, oral pathology, gastroenterology and gynecology ...
Cached Biology Technology:New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 2New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 3Midwest Health Care Startups Raise $315 Million in First Half of 2011 2Midwest Health Care Startups Raise $315 Million in First Half of 2011 3Midwest Health Care Startups Raise $315 Million in First Half of 2011 4Linden Enters Anatomic Pathology Sector Through Investment in Strata Pathology Services, Inc. 2
(Date:7/25/2014)... of diffusion tensor tractography (DTT), which is derived ... estimation for three motor tracts, such as the ... pathway became possible. The corticospinal tract is known ... function in the human brain. Several studies have ... transtentorial herniation. In addition, some studies have demonstrated ...
(Date:7/25/2014)... 2014 Biometrics industry expands and ... digital technology for online & commerce payments while seeking ... GOOG ), LifeLock Inc. (NYSE: ... Apple Inc. (NASDAQ: AAPL ) and Fortinet ... a biometric authentication company focused on the growing m-commerce ...
(Date:7/24/2014)... NY (July 24, 2014) Scientists at The ... are one step closer to creating a viable ... patient,s own cells. , For the first ... cells lines from skin samples of patients with ... an accelerated protocol to induce these stem cells ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Bethesda, MD (July 29, 2010): Today, the Association for Molecular ... for Information made by the National Institutes of Health (NIH) ... survey of its membership to formulate a comprehensive response to ... in a clinical laboratory setting, AMP is able to inform ...
... call "white graphene" may be the perfect sidekick for ... nanoscale electronics. But single-atom-thick layers of hexagonal boron ... University,s world-class Department of Mechanical Engineering and Materials Science, ... Researchers in the lab of Pulickel Ajayan, Rice,s ...
... CA July 28, 2010 For Immediate Release ... normally produced in the brain may provide the starting point ... epileptic seizures, according to a new study by scientists at ... a new angle for developing drugs to treat seizures," says ...
Cached Biology News:AMP responds to Genetic Test Registry request for information 2'White graphene' to the rescue 2Scripps research study opens the door to new class of drugs for epileptic seizures 2Scripps research study opens the door to new class of drugs for epileptic seizures 3
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Gentamicin sulfate, 5g...
Biology Products: